MedWatch

Bank bemused by Ambu downgrade

According to Handelsbanken, investor confidence in Ambu's credibility has suffered a blow after the company downgraded its guidance.

Photo: Ambu / PR

Analysts at the financial institution Handelsbanken are bemused that Ambu downgraded its guidance last year, since this move contrasts with announcements made by other contractors in the hospital sector, according to a stock exchange announcement from Handelsbanken on Monday.

On Thursday last week, Ambu downgraded its predicted guidance for the firm's organic growth and margin for earnings before interest and taxation for the staggered fiscal year 2020/2021 referring to the fact that the covid-19 pandemic is still affecting the number of operations being performed. This challenges the supply chain and causes delays.

Read the whole article

Get 14 days free access.
No credit card required.

An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP recommends nine new drugs, rejects one

Roche and Biogen are among the companies that have received recommendation for approval from the European Medicines Agency's committee (CHMP) at its September meeting. One Pfizer drug was the sole candidate to be rejected.

CEO at WSA: No clarity on EQT exit plans yet

The time horizon for the venture fund EQT's investment in WS Audiology should be ending soon, but according to Group CEO Eric Bernard, there is no clarity on when the potential changes might occur.

Further reading

Related articles

Trial banner

Latest news

See all jobs